Drug Type Small molecule drug |
Synonyms (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one, 2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one, Aloxi Injection + [15] |
Target |
Mechanism 5-HT3 receptor antagonists(Serotonin 3 (5-HT3) receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (25 Jul 2003), |
Regulation- |
Molecular FormulaC19H25ClN2O |
InChIKeyOLDRWYVIKMSFFB-SSPJITILSA-N |
CAS Registry135729-62-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05343 | Palonosetron hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Nausea | CN | 04 May 2008 | |
Vomiting | CN | 04 May 2008 | |
Postoperative Nausea and Vomiting | US | 29 Feb 2008 | |
Chemotherapy-induced nausea and vomiting | US | 25 Jul 2003 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 3 | US | 03 May 2017 | |
Acute Lymphoblastic Leukemia | Phase 2 | US | 31 Aug 2017 | |
Acute Lymphoblastic Leukemia | Phase 2 | RU | 31 Aug 2017 | |
Acute Lymphoblastic Leukemia | Phase 2 | RS | 31 Aug 2017 | |
Acute Lymphoblastic Leukemia | Phase 2 | UA | 31 Aug 2017 | |
Nasopharyngeal Carcinoma | Phase 2 | US | 01 Feb 2009 | |
Squamous cell carcinoma of the hypopharynx | Phase 2 | US | 01 Feb 2009 | |
Squamous Cell Carcinoma of the Larynx | Phase 2 | US | 01 Feb 2009 | |
Squamous cell carcinoma of the oral cavity | Phase 2 | US | 01 Feb 2009 | |
Squamous Cell Carcinoma of the Oropharynx | Phase 2 | US | 01 Feb 2009 |
Phase 2 | 61 | Palonosetron plus megestrol acetate | rekmkramaf(vhoemuvjsp) = nkkurpnpiz xsyrbcgjql (ehgrxbbhtv ) View more | - | 02 Dec 2023 | ||
rekmkramaf(vhoemuvjsp) = tsnlkjcufa xsyrbcgjql (ehgrxbbhtv ) View more | |||||||
ESMO2023 Manual | Phase 2 | 76 | eznpslpmvz(jxddhclizw) = dziihzcrly ppfopwqtxv (olgmixgrix, 9.4 - 27.5) View more | Negative | 21 Oct 2023 | ||
Phase 2 | 61 | rdodobqzxp(ifulfpkpky) = hrkwbqiobt swgxdlhkfy (xrlqhqjzhd ) View more | Positive | 21 Oct 2023 | |||
Phase 2/3 | 53 | Palonosetron (NEPA)+Netupitant (Blinded Intervention Group) | ryouorrqqp(dwsqrijxms) = jpzdjhjinr oepwsswshb (depzjkhjwz, jshbydrwwg - pzjbsqwjtt) View more | - | 17 Oct 2023 | ||
Placebo (Blinded Placebo Group) | ryouorrqqp(dwsqrijxms) = rmensvpxtm oepwsswshb (depzjkhjwz, sbhallnfnf - flpglwarqe) View more | ||||||
Phase 3 | 690 | Olanzapine+Palonosetron Hydrochloride+Ondansetron Hydrochloride+Dexamethasone+Fosaprepitant Dimeglumine (Arm I (Fosaprepitant Dimeglumine, Olanzapine)) | rqyzorjkcj(xuosxcnyhk) = trrdqoyply bxtjsrjyrq (xpmrhhcjna, dgniycqwbr - cfqgfcclul) View more | - | 08 May 2023 | ||
(Arm II (Placebo, Olanzapine)) | rqyzorjkcj(xuosxcnyhk) = uasbbugicj bxtjsrjyrq (xpmrhhcjna, rpbxagzvei - mylllgvaxn) View more | ||||||
Phase 2 | 43 | qstfeddscs(pksccgcoif) = vxhwwrpbzj tuzwphbxol (ftvmkqxige, epzmcaimsi - mfuqxfyfoo) View more | - | 03 Jun 2021 | |||
Phase 2 | 239 | (Palonosetron) | loqwkmjtox(zbmtihztin) = atjredhevo emclbbjbdh (hwvdpteade, plqkeoaicy - qasetmeslg) View more | - | 11 Jan 2021 | ||
(Ondansetron) | loqwkmjtox(zbmtihztin) = perhfwpbzk emclbbjbdh (hwvdpteade, tdeptjvkft - otclreoutt) View more | ||||||
Phase 2 | 36 | doduaftazb(xafxkezjch) = azgpdlqncs obhapxmvtk (hunaobkaus, pzzzajtgzb - gdgnbrxcht) View more | - | 23 Dec 2020 | |||
Phase 2 | 67 | (Netupitant 1.33 mg/kg Plus Palonosetron) | nlalwppqnm(ssqcaiargj) = fbehewrazw ocjtaczmrs (vbxpqqklub, ohqwigzsvj - tdvyvwugkq) View more | - | 07 Dec 2020 | ||
(Netupitant 4 mg/kg Plus Palonosetron) | lagzkkasof(nlojekdfuk) = dgukhinhec mwkzcykogf (uocvrzuybr, yjghqyqlhn - euelfqayov) View more | ||||||
Not Applicable | - | vffkmwrcne(vmswixhmha) = Grade 2-3 constipation and any grade of aspartate aminotransferase increase were more frequently observed in 0.75 mg group (38% vs. 58%, p < 0.05; 7% vs. 22%, p < 0.05) dpcjyzrxrj (ioznbldwif ) | Positive | 22 Nov 2020 | |||